SMURF1 and familial pancreatic carcinoma: These findings demonstrate that SMURF1 may be a potential therapeutic target for pancreatic cancer, providing new perspectives for evaluating the role of SMURF1 inhibitors in the clinical management of human pancreatic cancer.